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Up-regulation of extracellular matrix proteoglycans and colla- sive renal disease in general is the accumulation of inter-
gen type I in human crescentic glomerulonephritis. stitial collagens (that is, types I and III) in the lesions
Background. The pathogenesis of crescentic glomerulone- of glomerulosclerosis and interstitial fibrosis, implying aphritis (CGN) involves cellular migration and proliferation in
central pathogenic role for expansion and remodeling ofthe urinary space, frequently followed by fibrous organization.
the extracellular matrix in these processes. Another classExtracellular matrix proteoglycans (PGs) may regulate these
events via effects on cellular migration, interactions with growth of extracellular matrix molecules, the proteoglycans
factors, including transforming growth factor-b (TGF-b), and (PG), has multiple biologic properties that may be rele-
control of collagen fibrillogenesis. The expression of PG in
vant to the development and progression of CGN, in-human CGN is unknown.
cluding effects on cell adhesion and migration, modula-Methods. Renal tissues from 18 patients with CGN were
examined immunohistochemically for versican, decorin, bigly- tion of growth factor bioavailability, and regulation of
can and collagen type I, and were compared with morphologi- collagen fibrillogenesis [2]. The expression of PG in CGN
cally normal tissues from six tumor nephrectomies. Synthesis is largely unknown.of decorin, biglycan, and procollagen type I mRNAs was evalu-
Versican is a high molecular weight chondroitin sulfateated by in situ hybridization.
PG synthesized by smooth muscle cells, mesangial cells,Results. Versican was strongly expressed in cellular cres-
cents and periglomerular areas, whereas decorin and biglycan and fibroblasts, which is widely distributed in extracellu-
accumulated in collagen type I-enriched regions, including fi- lar matrices [2]. Versican is selectively expressed in em-
brocellular and fibrous crescents, and interstitial fibrosis. PG bryonic tissues that act as barriers to neural crest celland collagen type I accumulation colocalized with myofi-
migration and axonal outgrowth, suggesting a role inbroblasts in crescents, periglomerular areas, and interstitium.
Conclusions. The temporal and spatial patterns of expres- guiding cell migration [3]. Synthesis of versican may be
sion demonstrated in this study provide evidence to support required for smooth muscle cell proliferation in vitro [4],
pathogenic roles for PG in the evolution of CGN. Based on and versican accumulates in the neointima of atheroscle-
known biological properties of this molecule, versican may
rotic arteries, consistent with a role in the migrationfacilitate migration of cells in developing crescents. Decorin
and/or proliferation of smooth muscle cells during neo-and biglycan may contribute to progression of CGN, perhaps
via interactions with collagen type I in the remodeled extracel- intima formation [5]. Recently, versican has been shown
lular matrix. to function as a ligand for the leukocyte adhesion mole-
cule L-selectin in kidney tissue, suggesting a possible
role for versican in leukocyte trafficking in inflammatory
The pathogenesis of crescentic glomerulonephritis diseases of the kidney [6]. In normal adult human kidney,
(CGN) and the factors that determine progression to versican has been localized to the tubulointerstitium [5],
end-stage renal failure in some cases of CGN are incom- but its expression in glomerular disease is unknown.
pletely understood [1]. A pathologic hallmark of progres- Decorin and biglycan are members of the family of
small, leucine-rich chondroitin/dermatan sulfate PG that
may be particularly relevant to the pathogenesis of pro-Key words: decorin, biglycan, versican, inflammation, end-stage renal
failure, interstitial collagens, lesions, glomerulosclerosis, fibrosis. gressive renal disease [7]. A putative role for these mole-
cules in fibrosing disease has been inferred from theirReceived for publication February 7, 2000
ability to bind and inactivate the fibrogenic cytokineand in revised form August 7, 2000
Accepted for publication August 21, 2000 transforming growth factor-b (TGF-b) in some models
of fibrosing disease [7]. In the Thy 1 rat model of mesan-Ó 2001 by the International Society of Nephrology
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gioproliferative glomerulonephritis, synthesis of decorin nal biopsy tissues utilized for this study were fixed in
10% buffered formalin. The pathologic diagnosis in eachand biglycan is dramatically up-regulated in glomeruli,
possibly in response to increased TGF-b activity [8]. case was established by light microscopy, immunofluo-
rescence microscopy, and electron microscopy, usingAdministration of exogenous decorin [9] or transfection
of decorin cDNA into skeletal muscle to increase circu- standard techniques. The types of crescent identified in
Jones’ silver methenamine stained glomeruli were classi-lating levels of decorin [10] has been reported to reduce
proteinuria, ameliorate extracellular matrix accumula- fied as follows. Cellular crescents consisted of two or
more flattened layers of cells in the urinary space, with-tion, and decrease glomerular TGF-b levels [10], consis-
tent with a role for decorin as a negative regulator of out appreciable accumulations of extracellular matrix.
Fibrous crescents comprised abundant extracellular ma-TGF-b activity. Decorin may also have a role in fibrosing
disease via regulation of collagen fibrillogenesis, as indi- trix, with few if any identifiable nuclear profiles, and
were usually associated with obliteration of the adjacentcated by the demonstration of specific interactions be-
tween decorin core protein and collagen proteins in vitro glomerular capillary tufts and/or global glomerulosclero-
sis. Most cases also showed a variable number of fibro-[11], and the finding of abnormal collagen fibrillogenesis
in decorin-deficient mice [12]. Accumulation of decorin cellular crescents that contained, in addition to cells, a
variable amount of silver-positive extracellular matrix.in areas of interstitial fibrosis has been shown to correlate
with renal outcome in human glomerular diseases [13]. The percentage of glomeruli exhibiting glomeruloscle-
rosis (segmental or global) was evaluated in each case;The precise functions of biglycan are unknown. Like
decorin, its synthesis may be regulated by TGF-b and in many instances, sclerotic glomeruli also showed fea-
tures of fibrous crescent formation. Cases were subse-platelet-derived growth factor (PDGF) [14], both of
which have been implicated in human renal disease [15]. quently divided into two groups based on whether the glo-
meruli showed predominantly cellular crescents (groupBiglycan also may have roles in regulating TGF-b activ-
ity [16] and collagen fibrillogenesis [17]. Decorin has A, N 5 10) or predominantly fibrous crescents 6 sclero-
sis (group B, N 5 8; Table 1 and Fig. 1). The extent ofbeen localized to collagen-enriched areas in developing
and mature human kidney [13, 18], whereas biglycan was chronic tubulointerstitial injury, defined as interstitial
fibrosis, tubular dilation and/or atrophy, and associatedlocalized to a variety of cell types in human fetal kidney,
including tubular epithelium and glomerular endothelial mononuclear interstitial inflammatory cell infiltration
was graded semiquantitatively as follows: 0 5 no injury;cells, suggesting distinct roles for these molecules during
development [18]. We recently identified colocalization 1 5 involving ,25% of cortical area; 2 5 involving 25
to 75% of cortical area; and 3 5 involving .75% ofof decorin and biglycan with collagen type I in sclerosing
glomerular diseases of diverse etiology, and specific co- cortical area. For controls, macroscopically normal renal
tissues were obtained from nephrectomies for localizeddeposition of decorin and collagen type I in amyloid de-
posits [19]. The expression of decorin and biglycan in in- renal carcinoma.
flammatory human glomerular diseases, including CGN,
Antibodiesis unknown.
In this study, we sought evidence to support the hypoth- Rabbit polyclonal antibody specific for human versi-
can (VC-E) was provided by Dr. Richard Le Baron (Uni-esis that the temporal expression of versican, decorin,
and biglycan helps mediate the pathologic events in cres- versity of Texas, San Antonio, TX, USA) [20]. Polyclonal
rabbit antisera LF-51, LF-30/136, and LF-67 (to humancent formation by examining their expression in human
renal biopsies with features of CGN at different stages of decorin, human biglycan, and human collagen type I,
respectively) were kind gifts of Dr. Larry Fisher (Na-disease (represented by predominantly cellular crescents
and predominantly fibrous crescents, respectively). The tional Institute of Dental Research, Bethesda, MD,
USA). LF-30/136 was generated against a synthetic pep-distribution of these PGs was compared with the synthe-
sis and deposition of collagen type I and with the localiza- tide corresponding to amino acids 5 to 17 of the core
protein of human PG-II/decorin, conjugated to keyholetion of myofibroblasts and monocyte/macrophages in
these tissues and in morphologically normal kidney. limpet hemocyanin [21]. LF-51 was generated against a
synthetic peptide corresponding to amino acids 11 to 25
of the core protein of the secreted form of human bone
METHODS
proteoglycan I (PG-I)/biglycan, conjugated to bovine se-
Tissue selection and pathologic examination rum albumin (BSA) [22]. LF-67 was generated against
a synthetic C telopeptide antigen of the human collagenArchived paraffin-embedded diagnostic renal biopsy
tissues from cases of CGN in which there was remaining aI(I) chain, consisting of 26 amino acids, unconjugated
[23]. The specificities of these antisera have been pre-tissue in excess of that needed for patient diagnosis were
selected for study. Clinical data were obtained from the viously confirmed in Western blot and immunoprecipita-
tion experiments [20–24]. Additional staining was per-physician referral forms submitted with the biopsy. Re-
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Table 1. Clinical and pathologic characteristics of cases of crescentic glomerulonephritis (CGN) examined
Glomeruli C FC F
% global CD68 1/
%Casea Diagnosis sclerosis T.I.b Cresc.c
Group A
1 CGN 19(35) 2 15 6 6 5.7
2 CGN/ANCA 10(20) 2 10 60 0 9.3
3 CGN 8(0) 1 35 0 0 6.7
4 CGN 24(5) 2 60 0 0 10.1
5 CGN/IgAN 21(4) 0 10 10 5 15
6 CGN/IgAN 13(0) 0 14 0 0 4.0
7 CGN 6(0) 1 16 66 0 16
8 CGN 18(14) 1 38 36 6 10
9 CGN 42(5) 1 33 7 0 14.5
10 CGN/Lupus 14(7) 1 14 3 0 10.3
Mean (9%) 1.1 24.5 18.8 1.7 10.2
Group B
11 CGN/ANCA 20(50) 1 0 5 5 ND
12 CGN/ANCA 11(18) 2 0 46 0 ND
13 CGN 26(58) 2 12 8 16 5.5
14 CGN 48(12) 2 0 6 12 4.8
15 CGN 6(83) 2 0 0 66 ND
16 CGN/WG 17(25) 2 6 12 18 1.5
17 CGN 19(24) 1 0 50 16 4.5
18 CGN/Lupus 37(5) 1 0 13 3 16
Mean (34%) 1.62 2.2 17.5 17.0 6.5
a Group A, predominantly cellular CGN; Group B, predominantly fibrous CGN (CGN, crescentic glomerulonephritis; ANCA, antineutrophil cytoplasmic autoanti-
body present; WG, Wegener’s granulomatosis; IgAN, IgA nephropathy)
b T.I., chronic tubulointerstitial injury score (see text for scoring parameters); C, FC, F, percentage of glomeruli involved by cellular, fibrocellular and fibrous
crescents, respectively
c Average number of CD681 cells per crescent; ND, not done
used (both from Dako, Carpinteria, CA, USA), as pre-
viously described [25].
Immunohistochemistry
Sections were deparaffinized in xylene and rehydrated
in a descending ethanol series. Endogenous peroxidase
was quenched with 3% H2O2 for 10 minutes. For versi-
can, decorin, and biglycan staining, sections were di-
gested with chondroitinase ABC lyase (ICN Biomedi-
cals, Costa Mesa, CA, USA) at 250 mU/mL in 0.1 mol/L
Tris, 0.01% BSA, for 60 minutes at 378C. For collagen
type I staining, sections were digested in proteinase K
(5 mg/mL; Sigma, St. Louis, MO, USA) at 378C for 15
minutes. For CD68 staining, sections were heated with
Antigen Unmasking Solution (Vector, Burlingame, CA,
USA) in a household vegetable steamer for 20 minutes.
For polyclonal rabbit antibody staining, sections were
Fig. 1. Distribution of crescents by light microscopy in patients with blocked with normal goat serum for 10 minutes. Sections
predominantly cellular crescents (h) and those with predominantly were incubated with primary antibody, diluted in 1%
fibrous crescents (j).
BSA/phosphate-buffered saline (PBS) for one hour at
room temperature (dilutions 6-B-6, 1/100; LF-36/130,
1/250; VC-E, LF-51, LF-67, anticollagen I, 1/500), fol-
lowed by a biotinylated goat anti-rabbit antibody (Vec-formed using commercial antibodies to decorin (6-B-6,
tor) or biotinylated horse anti-mouse (Vector), andmonoclonal mouse antihuman dermatan sulfate PG; Sei-
ABC-Elite reagent (Vector). The reaction product wasgaku, Tokyo, Japan) and collagen type I (polyclonal rab-
visualized with 3,39 diaminobenzidine (Sigma) and nickelbit anti-human; Chemicon, Temecula, CA, USA). For
chloride enhancement. The slides were counterstaineda-smooth muscle actin (a-SMA) and CD68 immuno-
staining, commercial murine antihuman antibodies were with methyl green. The immunohistochemical staining
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in each case was graded by an observer who was blinded washes with 0.1 3 SSC/0.1% Tween 20 (Sigma) at 508C,
and several 2 3 SSC washes. The slides were dipped into the histopathologic diagnosis. A score was assigned
to each individual glomerulus as follows: 0 5 no staining NTB2 nuclear emulsion (Kodak, Rochester, NY, USA)
and exposed in the dark at 48C for one to four weeks.product visualized; 1 5 weak and/or segmental staining;
and 2 5 strong and/or global staining. The final score After developing, sections were counterstained with he-
matoxylin and eosin, dehydrated, and coverslipped. Posi-(S) per section was calculated as the weighted mean,
tive cellular labeling was defined as five or more silver
S 5 (N1 3 0 1 N2 3 1 1 N3 3 2)/(N1 1 N2 1 N3) grains in a single cell. For negative controls, simultaneous
hybridization with the sense riboprobe was performedwhere Ni (i 5 1 to 3) is the number of glomeruli in each
category. Negative controls for immunohistochemistry on replicate tissue sections.
included substitution of the primary antibody with equal
Statistical analysisamounts of an irrelevant rabbit or mouse IgG (Dako).
The values of the groups are expressed as means 6
Molecular probes SEM. Data were analyzed for statistical significance by
Student t test, assuming unequal variances, using SPSSTwo pBluescript SK plasmids, containing either hu-
man bone decorin cDNA (plasmid P2) or human bone program 9.0. A P value ,0.05 was considered significant.
biglycan cDNA (plasmid P16), were generous gifts of
Dr. Larry Fisher (National Institute of Dental Research).
RESULTS
Plasmid p16 contains a 1658 bp insert with the complete
General observations: Clinicopathologic diagnosesprotein-encoding sequence of the human biglycan gene
[21]. Plasmid p2 contains a 1.6 kb insert with the protein- Specific clinicopathologic diagnoses in four cases in-
cluded diffuse proliferative lupus nephritis (WHO Classencoding sequence of the human decorin gene [21]. A
1.8 kb cDNA coding for human pro-aI(I) chain of type IV, N 5 2), Henoch-Scho¨nlein purpura (N 5 1), and
recurrent active Wegener’s disease (N 5 1). One biopsy,1 procollagen (Hf677) [26, 27] was subcloned in pcDNA3
(Invitrogen, Carlsbad, CA, USA), and the sequence was obtained from a 14-year-old girl with features of a pulmo-
nary–renal syndrome and a positive perinuclear-ANCAconfirmed by dideoxy sequencing. The plasmids were lin-
earized with Xba I and Kpn I (p16), BamH I and Kpn I (pANCA) test, showed limited mesangial IgA deposits
that were interpreted as suggestive of subclinical IgA(P2), and Hind III and Xba I (Hf677) and were transcribed
into both antisense and sense (negative control) ribo- nephropathy, with a superimposed antineutrophil cyto-
plasmic antibody (ANCA)-related CGN. Three addi-probes in T3-, T7-, or SP6-primed reactions [21] using
reagents from Promega (Madison, WI, USA; except tional cases were diagnosed as ANCA-related CGN. In
the remaining 10 individuals, the results of serologic test-35S-UTP; New England Nuclear, Boston, MA, USA).
ing for ANCA and for antiglomerular basement mem-
In situ hybridization brane (GBM) antibodies were not available at the time
of biopsy, and these cases were diagnosed as CGN ofFormalin-fixed, paraffin-embedded tissues were de-
paraffinized following standard protocol. The sections nonimmune complex or pauci-immune complex type.
These data are summarized in Table 1.were washed with 0.5 3 standard sodium citrate (SCC;
GIBCO, Grand Island, NY, USA) and digested with 5
Pathologic examination: General observationsmg/mL proteinase K (Sigma) in Tris buffer (500 mmol/L
NaCl, 10 mmol/L Tris, pH 8.0) for 30 minutes at 378C. Pathologic findings are summarized in Table 1 and
Figures 1 and 2. All biopsies showed segmentally necro-Several 0.5 3 SCC washes were followed by prehybrid-
ization for two hours in 50 mL of prehybridization buffer tizing and CGN (mean 45% of glomeruli involved by
crescents, range 16 to 83%), with varying degrees of[50% formamide, 0.3 mol/L NaCl, 20 mmol/L Tris, pH
8.0, 5 mmol/L ethylenediaminetetraacetic acid (EDTA), glomerulosclerosis (mean 20.7%, range 0 to 83%). The
distribution of different crescent types in groups A and1 3 Denhardt’s solution, 10% dextran sulfate, 10 mmol/L
dithiothreitol (DTT), 500 mg/mL yeast tRNA] at 508C. B is illustrated in Figure 1. Predictably, the percentage
of glomerulosclerosis was greater in group B (34.4 6 9.4The hybridization was started by adding 500,000 cpm of
35S-labeled riboprobe in 50 mL of prehybridization buffer vs. 9 6 3.5, P , 0.05), as was the chronic tubulointerstitial
injury score (1.6 6 0.2 vs. 1.2 6 0.2, P 5 0.09). Theand was allowed to proceed overnight at 508C. The
hybridization was started by adding 500,000 cpm of degree of interstitial fibrosis, tubular atrophy, and arte-
riosclerosis in individual cases was generally commensu-35S-labeled riboprobe in 50 mL of prehybridization buf-
fer and allowed to proceed overnight at 508C. Sections rate with the severity of glomerulosclerosis. Rupture of
Bowman’s capsule basement membrane was identifiedwere then washed with 0.5 3 SSC followed by RNase
A (20 mg/mL, 30 minutes at room temperature), 2 3 in 15 cases. Features of arterial vasculitis were not identi-
fied in any case.SSC washes (2 3 2 minutes), three high-stringency
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B (0.36 6 0.13 vs. 0.72 6 0.2, P 5 0.2). These scores
reflect the inclusion of decorin staining in fibrocellular
crescents (Fig. 4A) and in globally sclerotic glomeruli in
both groups. Decorin was not clearly identified in cellular
crescents. Decorin also accumulated in areas of intersti-
tial fibrosis. Decorin mRNA expression was localized to
cells at sites of decorin accumulation, in fibrocellular and
fibrous crescents (Fig. 4B), and in sclerotic glomeruli. In
the interstitium decorin mRNA was localized to peri-
tubular interstitial cells (Fig. 4C) with morphologic fea-
tures of fibroblasts or myofibroblasts [28], but was not
identified in tubular epithelial cells or in infiltrating
mononuclear inflammatory cells.
Biglycan was not identified by immunohistochemistry
in morphologically normal glomeruli or in tubular epi-
thelial cells. Biglycan accumulated in fibrous crescents
and sclerotic glomeruli (Fig. 5A) and in the interstitium,
in a pattern similar to that of decorin, with accentuation
Fig. 2. Immunostaining scores for versican, decorin, biglycan, and col- in perivascular adventitia and in areas of fibrosis. Similar
lagen type I in glomeruli of patients with crescentic glomerulonephritis to decorin, the glomerular staining score for biglycan(CGN). Symbols are: (h) patients with predominantly cellular crescents;
was also increased in group B (0.43 6 0.07 vs. 0.8 6 0.14,(j) those with predominantly fibrous crescents.
P 5 0.05). Biglycan, but not decorin, also accumulated
in the neointima of arteriosclerotic vessels in a pattern
similar to that of versican. Biglycan mRNA was strongly
Immunolocalization of versican expressed by parietal epithelial cells (Fig. 5B) and by oc-
casional intracapillary glomerular cells (either mesangialIn normal kidney (obtained from tumor nephrectomy
specimens), versican showed a patchy distribution in the and/or endothelial cells) in morphologically normal glo-
meruli. An intense signal for biglycan mRNA was identi-interstitium, with accentuation of staining around glo-
meruli and in perivascular adventitia, but was not identi- fied in the majority of both cellular and fibrocellular cres-
cents (Fig. 5C). Biglycan mRNA was also widely expressedfied in normal glomeruli or in tubular epithelium. Versi-
can was identified in cellular crescents, in some cases by interstitial fibroblasts/myofibroblasts (Fig. 5D) and by
neointimal cells and occasional endothelial cells (dataaccompanied by focal staining in the glomerular tuft
adjacent to crescents (Fig. 3). Versican was also present not shown). Biglycan mRNA was not identified in tubu-
lar epithelial cells or in infiltrating leukocytes.in fibrous crescents. The overall glomerular versican
staining score was slightly increased in cases with pre-
In situ hybridization and immunolocalization ofdominantly cellular crescents (group A) compared with
collagen type Icases with predominantly fibrous crescents (group B,
0.62 6 0.1 vs. 0.50 6 0.1, P 5 0.5). Mesangial areas in Collagen type I accumulated in fibrous crescents, in
sclerotic glomeruli, and in areas of interstitial fibrosis inmost glomeruli were negative. Globally sclerotic glomer-
uli were typically negative for versican, except where these a distribution similar to that of decorin and biglycan
(Fig. 6A). Glomerular staining was increased in groupalso showed fibrous crescent formation. There was patchy
interstitial staining for versican, particularly in perivascu- B (0.38 6 0.1 vs. 0.56 6 0.1, P 5 0.2). Procollagen type
I mRNA was not identified in normal-appearing glomer-lar adventitia, in a pattern similar to that seen in normal
kidney. There was no apparent difference in the intensity uli. In CGN, an intense signal for procollagen type I
mRNA was identified in a subpopulation of crescentor distribution of versican accumulation in the interstitium
in cases with predominantly cellular crescents and those cells, typically spindle shaped cells in fibrocellular or
fibrous crescents (Fig. 6B), but also focally in some cellu-with predominantly fibrous crescents. Diffuse accumula-
tions of versican were noted in the neointima of arterio- lar crescents. Because of the complexity of the crescentic
lesions, it was unclear whether some mesangial cells insclerotic vessels (data not shown).
these cases also expressed procollagen type I. In general,
Immunolocalization and in situ hybridization for the number of crescent cells expressing procollagen type
decorin and biglycan I mRNA was fewer than those expressing biglycan
mRNA (compare Fig. 6B with Fig. 5C). Procollagen typeDecorin protein and mRNA were not identified in
morphologically normal-appearing glomeruli. The glo- I mRNA also localized to spindle-shaped cells in the
interstitium and periglomerular areas.merular decorin staining score was increased in group
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Fig. 3. (A) Versican accumulation in cellular crescent. Note also staining in adjacent glomerular tuft. (B) Versican accumulation in fibrous crescent.
Fig. 4. (A) Decorin accumulation in fibrous crescent and adjacent areas
of interstitial fibrosis. (B) Decorin mRNA expression (black grains) by
occasional cells within the crescent (same case as in Fig. 1A). (C )
Decorin mRNA expression in peritubular interstitial cells.
Localization of a-SMA–positive cells and CD68 (Fig. 7A), with variable, frequently numerous a-SMA1
positive cells (macrophage/monocytes) cells in fibrocellular and fibrous crescents (Fig. 7A, B).
a-SMA1 cells were mostly absent from cellular cres-In both normal and disease tissues, a-SMA was widely
cents. Some glomeruli were encircled by a-SMA1 cellsexpressed by vascular smooth muscle cells and by occa-
that focally extended into the underlying crescentsional interstitial cells with the morphologic appearance
through breaks in Bowman’s capsule (Fig. 7B). Occa-of fibroblasts/myofibroblasts. In addition, rare intra-
sional CD68-positive cells were present both within cap-glomerular cells in morphologically normal glomeruli
illary loops and in the urinary space of morphologicallystained for a-SMA. Most crescentic glomeruli showed
enhanced immunostaining for a-SMA in mesangial areas normal glomeruli and within interstitial inflammatory
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Fig. 5. (A) Biglycan accumulation in a partial fibrous crescent. (B)
Biglycan mRNA expression in a cellular crescent (outlined by arrow-
heads). (C ) Biglycan mRNA expression in peritubular interstitial cells.
cell infiltrates. Significant numbers of CD68-positive cells mRNA expression overlapped with the distribution of
a-SMA1 cells in the peritubular interstitium and in cres-were identified in most crescents (mean 8.9, range 1.5
to 16), but in no case were they the predominant cell cents. Biglycan mRNA was also strongly expressed by
type (Fig. 7C). Glomerular CD681 cells were more nu- parietal epithelial cells in normal glomeruli that lacked
merous in group A (10.2 6 1.3 vs. 6.5 6 2.5, P 5 0.2). a-SMA1 cells. In replicate tissue sections, procollagen
type I mRNA expression overlapped with the presence
Serial immunohistochemical staining of a-SMA1 cells, in crescents and in interstitium, and
Replicate tissue sections were stained for versican, also possibly in mesangial areas adjacent to crescents.
decorin, biglycan, CD68, and a-SMA (Fig. 8). Versican,
decorin, and biglycan codistributed with a-SMA–positive
DISCUSSIONcells in fibrocellular and fibrous crescents (data not
The molecular and cellular events mediating crescentshown), in the interstitium, and in neointimal thickenings
formation have recently been reviewed [1]. These in-of arteries (versican and biglycan only). However, versi-
clude synthesis of chemotactic molecules {for example,can was also identified in cellular crescents that did not
monocyte chemoattractant protein-1 (MCP-1) [29] andcontain appreciable numbers of a-SMA1 cells (Fig. 8A),
ostopontin [30, 31]}, up-regulation of leukocyte adhesionand versican was not detected in mesangial areas, many
molecules [32], macrophage proliferation [33], and ex-of which contained numerous a-SMA1 cells (Fig. 8D).
pression of prosclerotic growth factors, including PDGFNo apparent association was observed between the pres-
[34] and TGF-b [35, 36]. Rupture of Bowman’s capsuleence of CD681 cells and versican, decorin, and biglycan
[37, 38], which is associated with, and may be relatedaccumulations in crescents, interstitium, or neointimal
to macrophage accumulation in Bowman’s space [1], isthickenings.
followed by the influx of fibroblasts or myofibroblastsAttempts to characterize the phenotype of decorin,
from the interstitium, and these cells may synthesize thebiglycan, and procollagen mRNA1 cells using combined
interstitial collagens (types I and III) that accumulate inimmunohistochemical staining/in situ hybridization tech-
fibrocellular and fibrous crescents [37, 39]. In experimen-niques were unsuccessful. Examination of replicate tis-
sue sections demonstrated that decorin and biglycan tal CGN, procollagen I mRNA synthesis is up-regulated
Stokes et al: Prosteoglycans in CGN 539
Fig. 6. (A) Collagen type I accumulation in fibrous crescents in a pat-
tern similar to that of decorin (Fig. 3A) and biglycan (Fig. 4A). (B)
Procollagen type I mRNA is strongly positive in cellular crescents. (C )
Procollagen type I mRNA expression by peritubular interstitial cells.
in extraglomerular compartments early in the course of cell migration by interfering with cell attachment to vari-
ous substrata, including fibronectin, collagen, and lami-disease [40], followed by its expression in periglomerular
areas and in Bowman’s space [41], suggesting that colla- nin [2]. Others have localized hyaluronate in experimen-
tal CGN [42, 43], and it is possible that versican/gen-synthesizing cells migrate across Bowman’s capsule
from the interstitium as crescents undergo fibrous orga- hyaluronate may have a role in the migration of leuko-
cytes during crescent formation, perhaps via interactionsnization. The present study demonstrates that PG syn-
thesis and deposition occur in human CGN, and these with CD44 and/or L-selectin expressed on the surface of
infiltrating leukocytes [6]. Although we did not identifymolecules may contribute to the fate of crescents and
renal outcome. a-SMA1 myofibroblasts may contribute a spatial relationship between versican deposition and
CD681 cells within individual crescents, the finding thatto the accumulations of PG and collagen type I, as evi-
denced by their overlapping patterns of distribution in glomerular staining for versican was increased in cases
with predominantly cellular crescents that also showedfibrous/fibrocellular crescents and in interstitial fibrosis.
However, we did not positively identify the crescent cell increased numbers of glomerular CD681 cells suggests
that these events are related. In all likelihood, the hightype(s) responsible for matrix molecule synthesis and
specifically cannot exclude a contribution from native glo- frequency of chronic disease in the human renal tissues
studied (as evidenced by the frequent finding of fibrocel-merular mesangial and/or epithelial cells in many cases.
We present evidence that versican may have a role in lular crescents and chronic tubulointerstitial injury in all
cases) will tend to obscure whatever associations maycellular migration during the evolution of CGN. The
localization of versican to cellular crescents provides exist between PG accumulation and the early stages of
CGN. These results are also consistent with a pathogenicstrong evidence for a pathogenic role for versican in
CGN. Versican has previously been localized to the in- role for versican in fibrous crescent formation, perhaps
related to effects on migration of a-SMA1 myofi-terstitium and periglomerular regions of adult human
kidney, but was not identified in normal glomeruli or broblasts in human CGN. This interpretation is consis-
tent with in vitro observations that migration and mitosistubules [5]. Versican forms a loose, highly hydrated ex-
tracellular matrix with hyaluronic acid and may facilitate of smooth muscle cells is dependent on the formation
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Fig. 7. (A) Anti-smooth muscle actin (anti-SMA)–positive cells in mes-
angial areas and adjacent fibrocellular crescent. (B) Anti-SMA–positive
cells around glomerulus and extending into crescent. (C ) Anti-CD68–
positive cells in a predominantly cellular crescent.
of a versican-enriched pericellular matrix [4]. Up-regula- activity at sites of fibrosing injury. Binding of TGF-b by
decorin/biglycan may serve a reservoir function, contrib-tion of versican in CGN may be linked to the activity of
TGF-b [35, 36, 44] and PDGF [34, 45] in CGN, consistent uting to a locally high concentration of this growth factor
in the extracellular matrix [9], or alternately sequesteringwith in vitro evidence demonstrating regulation of versi-
can synthesis by smooth muscle cells in response to these the growth factor and thereby limiting its local effects.
PG binding may have activating as well as suppressantgrowth factors [46].
The overlapping distribution patterns of decorin and effects on TGF-b activity [2], and the biologic signifi-
cance of PG accumulations at sites of fibrosing injurybiglycan with collagen type I in fibrous crescents and
interstitial fibrosis strongly suggest a role for these PG remains undetermined. Nonetheless, this study is consis-
tent with a pathogenic role(s) for PG in progressive renalrelated to collagen fibrillogenesis at these sites. Although
collagen fibrillogenesis is largely a self-assembly process disease related to CGN. Of note, we observed distinct
patterns of decorin and biglycan mRNA expression. Glo-determined by the primary amino acid sequence of the
collagen molecules themselves, this process may be mod- merular expression of decorin mRNA was limited to
occasional cells in fibrous crescents and in sclerotic glo-ulated by other extracellular molecules, including de-
corin and biglycan. Ultrastructural studies confirm a meruli, whereas constitutive synthesis of biglycan
mRNA was identified in nondiseased glomeruli, mostclose relationship between a small interstitial PG, puta-
tively identified as decorin, and collagen fibrils [47], and consistently in parietal epithelial cells, but also in a lim-
ited number of other glomerular cells. Biglycan mRNAdecorin knockout mice manifest bizarre collagen mor-
phology [12], supporting a role for decorin in maintaining expression was strikingly up-regulated in crescents, in-
cluding cellular crescents. While we have speculated oninterfibrillar spacing [2]. Although the function of bigly-
can in collagen fibrillogenesis is less well understood, the importance of these molecules for growth factor ac-
tivity that might mediate evolution of the injury process,the existence of biologically relevant biglycan/collagen
interactions is supported by the observation that biglycan the actual significance of these observed differences in
PG expression remains unclear.codeposits with collagen type I in some models of fibros-
ing disease [24, 48]. In addition to a role in collagen fibril- In summary, we report PG expression in human CGN
and progressive renal fibrosis. Versican synthesis is up-logenesis, decorin and biglycan may modulate TGF-b
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Fig. 8. (A) Versican accumulation is seen in
a predominantly cellular crescent. (B) In a
replicate tissue section, no decorin is localized
within the crescentic glomerulus. (C) Bigly-
can-positive cells can be seen in the intersti-
tium, but not in the crescent in a replicate
tissue section. (D) Anti-SMA–positive cells
can be seen in the mesangial area of the glo-
merular tuft, and a few SMA-positive cells can
be seen in the crescent. (E) Anti-CD68–
positive cells can also be seen in both the
crescent and the tuft.
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